HC Surgical Specialists Ltd (1B1) AI Stock Analysis

• Market Cap: S$58.45M
• Dividend Yield: 3.37%
• Average Volume (3M): 50.29K
• Price to Earnings (P/E): 6.5
• Beta (1Y): -0.03
• Revenue Growth: 1.58%
• EPS Growth: 115.29%
• Country: SG
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 156,309,900
• 10 Day Avg. Volume: 16,820
• 30 Day Avg. Volume: 50,290
• PEG Ratio: 0.04
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 2.29
• P/FCF Ratio: 6.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: S$0.41 ▲(14.44% Upside)

The overall stock score is driven by strong financial performance, particularly in profitability and equity utilization, despite revenue and cash flow challenges. The valuation is attractive with a low P/E ratio and high dividend yield. Technical indicators suggest neutral momentum with potential for upward movement.

Positive Factors

Profitability

High profit margins indicate efficient operations and strong pricing power, supporting long-term financial health and shareholder returns.

Board Restructuring

The board restructuring aims to enhance governance and strategic direction, potentially improving decision-making and long-term company performance.

Cash Generation

Strong cash flow generation supports operational flexibility and the ability to invest in growth opportunities, enhancing long-term sustainability.

Negative Factors

Revenue Decline

Declining revenue suggests challenges in market demand or competitive positioning, potentially impacting long-term growth prospects.

Free Cash Flow Growth

Negative free cash flow growth can limit the company's ability to reinvest in the business and may affect financial stability over time.

Non-operational Profit Gains

Reliance on non-operational gains for profit growth may not be sustainable, posing risks to consistent long-term profitability.

HC Surgical Specialists Ltd Business Overview & Revenue Model

Company Description

HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics. It also offers treatment services for other conditions, such as haemorrhoids, anal fissure, hernia, anal abscess, cholecystitis, anal fistula, appendicitis, colorectal cancer, lipomas, cysts, and gastric cancer, vein laser vascular, laparoscopy, and other general and specialized medical services. In addition, the company provides orthopedic services comprising joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, wounds/lumps, tenosynovitis, tunnel syndrome, bumps, joint replacement, arthroscopic surgery, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, fractures, and orthobiologic injections. Further, it provides home care services, which include medical, nursing, physiotherapy, speech therapy, occupational therapy, and ambulance services; health screening, management of acute and chronic conditions, and pre-employment check-up; public health preparedness clinic scheme, swab and send home program, community health assist scheme, and COVID-19 swab test services. Additionally, the company offers diagnostic tests that comprise blood tests, X-Rays, ultrasound, CT scans, and MRIs. HC Surgical Specialists Limited was incorporated in 2015 and is based in Singapore.

How the Company Makes Money

HC Surgical Specialists generates revenue primarily through the provision of surgical services. The company charges fees for surgical procedures performed by its qualified specialists, which can include consultations, surgeries, and follow-up care. Additionally, HC Surgical Specialists may earn income through partnerships with hospitals and healthcare facilities where their specialists perform surgeries. The company could also have revenue streams from the sale of related medical products or technologies used in their procedures. Key factors contributing to its earnings include the growing demand for minimally invasive surgical options, the expansion of its specialty services, and its reputation for high-quality patient care, which can lead to increased patient referrals.

HC Surgical Specialists Ltd Financial Statement Overview

Summary

HC Surgical Specialists Ltd demonstrates strong profitability with high net and EBIT margins, and effective equity utilization with low financial leverage. However, challenges include declining revenue and negative free cash flow growth.

Income Statement

The company shows strong profitability with a high net profit margin of 44.16% and a solid EBIT margin of 46.78%. However, revenue growth has been negative, indicating a decline in sales over the past year. Despite this, the gross profit margin remains robust at 84.32%, suggesting efficient cost management.

Balance Sheet

The balance sheet reflects a healthy debt-to-equity ratio of 0.13, indicating low leverage and financial stability. The return on equity is impressive at 40.28%, showcasing effective utilization of equity. However, the equity ratio is not explicitly calculated, which could provide additional insights into asset financing.

Cash Flow

Operating cash flow is strong with a coverage ratio of 1.49, indicating good cash generation relative to net income. Free cash flow growth is negative, which is a concern, but the free cash flow to net income ratio is high at 93.29%, reflecting efficient cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.30M	19.11M	18.81M	19.08M	19.31M	23.47M
Gross Profit	8.92M	16.11M	15.96M	16.45M	16.67M	12.86M
EBITDA	5.87M	10.88M	7.01M	5.96M	9.59M	9.69M
Net Income	8.44M	8.44M	3.85M	2.92M	6.38M	8.00M
Balance Sheet
Total Assets	27.27M	27.27M	27.84M	31.26M	30.96M	36.28M
Cash, Cash Equivalents and Short-Term Investments	5.73M	5.73M	8.06M	10.26M	6.93M	11.17M
Total Debt	2.78M	2.78M	4.34M	5.50M	6.25M	8.04M
Total Liabilities	6.52M	6.52M	13.37M	19.18M	19.74M	25.53M
Stockholders Equity	20.95M	20.95M	14.69M	12.10M	11.00M	9.83M
Cash Flow
Free Cash Flow	6.75M	6.75M	6.23M	6.51M	6.83M	10.24M
Operating Cash Flow	7.23M	7.23M	6.30M	7.22M	7.05M	10.75M
Investing Cash Flow	-444.00K	-444.00K	2.84M	-1.72M	-1.99M	-811.00K
Financing Cash Flow	-9.05M	-9.05M	-7.97M	-6.24M	-9.12M	-5.74M

HC Surgical Specialists Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:1B1, the sentiment is Positive. The current price of 0.36 is below the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.36, and above the 200-day MA of 0.32, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.86 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:1B1.

HC Surgical Specialists Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1B1	67 Neutral	S$58.45M	6.46	47.36%	3.37%	1.58%	115.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HC Surgical Specialists Ltd Corporate Events

HC Surgical Specialists Lifts Half-Year Profit on Investment Gains, Declares Interim Dividend

HC Surgical Specialists reported revenue of S$9.78 million for the six months ended 30 November 2025, slightly down 1.6% year-on-year, while profit attributable to shareholders rose 17.5% to S$3.97 million and earnings per share increased to 2.59 Singapore cents. The stronger bottom line was driven mainly by non-operational gains, including a higher fair value gain on financial assets at fair value through profit or loss and the absence of prior-year fair value losses on derivative financial instruments and losses from deemed disposal in an associate, and the board declared an interim dividend of S$0.009 per ordinary share, underscoring continued shareholder returns despite flat operating performance.

The most recent analyst rating on (SG:1B1) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on HC Surgical Specialists Ltd stock, see the SG:1B1 Stock Forecast page.